Grant of Options

Incanthera PLC
22 February 2024
 

Goal Group


22 February 2024

Incanthera plc

("Incanthera" or the "Company")

Grant of Options

Incanthera plc, the specialist company focused on dermatology and oncology announces the grant of  3,200,000 options, on 21 February 2024, to directors, senior management and employees under both its approved and unapproved share option schemes (the "Schemes") as follows:

 

Option holder (scheme)

Number of Options granted

Exercise Price

Options Granted as Percentage of Current Issued Share Capital

Tim McCarthy

(Approved)

                  650,000

8.75p

0.71%

Simon Ward

(Approved)

                  650,000

8.75p

0.71%

Suzanne Brocks

(Approved)

                  650,000

8.75p

0.71%

Laura Brogden

(Unapproved)

                  650,000

8.75p

0.71%

Caroline Murray

(Unapproved)

                  200,000

8.75p

0.22%

 

Option Schemes and Grant of Options

The Company adopted the Schemes in 2020, to incentivise management performance for the benefit of all shareholders by way of options which are subject to time and performance conditions.  

For the purposes of the Schemes, a maximum of 10 per cent. of the Company's issued share capital in aggregate, from time to time, may be issued.

Vesting criteria for options granted under the Schemes are subject to time and performance conditions as follows:

Amount Vesting

Time Condition

34 per cent. ("Tranche One")

On the first anniversary of the date of the grant 

33 per cent. ("Tranche two")

On the second anniversary of the date of the grant

33 per cent. ("Tranche three")

On the third anniversary of the date of the grant

 

 

Performance Condition: Posting of First revenues from a commercial deal

The Schemes provide for good/bad leaver provisions and other standard terms normally associated with such schemes. 

Following the grant of options above, the Company will have in total outstanding options over 9,175,000 ordinary shares, representing 9.96 per cent. of the Company's issued share capital. The issued share capital of the Company comprises 92,109,880 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

For further information, please contact:

 

Incanthera plc

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

 

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600



Aquis Exchange Corporate Adviser: 

Cairn Financial Advisers LLP

Jo Turner / Liam Murray

+44 (0) 20 7213 0880

 


Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney

+44 (0) 20 3650 3650/51

 

  

1.

Details of the person discharging managerial responsibilities/person closely associated


 Name

 


1.    Tim McCarthy

Chairman

2.    Simon Ward

CEO

3.    Caroline Murray

Director



2.

Reason for the notification

a)

Position/status

As above

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Incanthera plc

b)

LEI

2138002HEV4UFBOEXQ97

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over ordinary shares

b)

Identification code

GB00BGL7YW15

c)

Nature of the transactions

Grant of Options 

d)

Volumes and Prices

 

Volume

Price

1.    650,000

8.75p

2.    650,000

8.75p

3.    200,000

8.75p

 

e)

Aggregated information

-     Aggregated volume

-     Price

 

Volume

Prices

1,500,000

 

8.75p

 

f)

Date of the transactions

21 February 2024

g)

Place of the transactions

AQSE Growth Market, UK

                       

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                               

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings